FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Fischer

Research Profile

Chemicals & Drugs

Disorders

Procedures

Physiology

Concepts & Ideas

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Michael Koehler; Thomas Fischer; Joerg Frommer
Caught by an acute leukaemia: facing patients' own experiences.
Daniel B Lipka; Junia V Melo; Carsten Müller-Tidow; Mirle Schemionek; Tina Schnöder; Marie-Christine Wagner; Marek Dziadosz; Florian Heidel; Thomas Kindler; Steffen Koschmieder; Thomas Fischer
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
Michael Koehler; Katharina Koehler; Michael Koenigsmann; Nicole Kreutzmann; Thomas Fischer; Jörg Frommer
Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Fischer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael Koehler; Thomas Fischer; Joerg Frommer
Caught by an acute leukaemia: facing patients' own experiences.
Leukemia research 2013;37(5):481-2.
2012: Daniel B Lipka; Junia V Melo; Carsten Müller-Tidow; Mirle Schemionek; Tina Schnöder; Marie-Christine Wagner; Marek Dziadosz; Florian Heidel; Thomas Kindler; Steffen Koschmieder; Thomas Fischer
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
PloS one 2012;7(7):e40853.
2011: Michael Koehler; Katharina Koehler; Michael Koenigsmann; Nicole Kreutzmann; Thomas Fischer; Jörg Frommer
Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2011;16(1):5-13.
2010: Thomas Kindler; Daniel B Lipka; Thomas Fischer
FLT3 as a therapeutic target in AML: still challenging after all these years.
Blood 2010;116(24):5089-102.
2010: B Markova; C Albers; F Breitenbuecher; J V Melo; T H Brümmendorf; Florian Heidel; D Lipka; J Duyster; Christoph Huber; Thomas Fischer
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Oncogene 2010;29(5):739-51.
2009: Sabine Kayser; Richard F Schlenk; Martina Correa Londono; Frank Breitenbuecher; Kerstin Wittke; Juan Du; Silja Groner; Daniela Späth; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Thomas Fischer; Konstanze Döhner
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
Blood 2009;114(12):2386-92.
2009: Frank Breitenbuecher; Boyka Markova; Stefan Kasper; Birgit Carius; Torsten Stauder; Frank D Böhmer; Kristina Masson; Lars Rönnstrand; Christoph Huber; Thomas Kindler; Thomas Fischer
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Blood 2009;113(17):4063-73.
2009: Frank Breitenbuecher; Susanne Schnittger; Rebekka Grundler; Boyka Markova; Birgit Carius; Alexandra Brecht; Justus Duyster; Torsten Haferlach; Christoph Huber; Thomas Fischer
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood 2009;113(17):4074-7.
2008: Stefan Kasper; Frank Breitenbuecher; Yvette Hoehn; Florian Heidel; Daniel B Lipka; Boyka Markova; Christoph Huber; Thomas Kindler; Thomas Fischer
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Leukemia research 2008;32(11):1698-708.
2008: Daniel B Lipka; Linda S Hoffmann; Florian Heidel; Boyka Markova; Marie-Christine Blum; Frank Breitenbuecher; Stefan Kasper; Thomas Kindler; Ross Levine; Christoph Huber; Thomas Fischer
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.
Molecular cancer therapeutics 2008;7(5):1176-84.
2008: Daniel Lipka; Florian Heidel; Christoph Huber; Thomas Fischer
[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Pharmazie in unserer Zeit 2008;37(5):394-403.
2007: Stefan Kasper; Thomas Kindler; Sebastian Sonnenschein; Frank Breitenbuecher; Frank D Böhmer; Christoph Huber; Thomas Fischer
Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2007;27(11):947-59.
2007: Daniel Drescher; Markus Moehler; Ines Gockel; Kirsten Frerichs; Annett Müller; Fritz Dünschede; Thomas Borschitz; Stefan Biesterfeld; Martin H Holtmann; Thomas Wehler; Andreas Teufel; Kerstin Herzer; Thomas Fischer; Martin R Berger; Theodor Junginger; Peter R Galle; Carl C Schimanski
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?
World journal of gastroenterology : WJG 2007;13(26):3605-9.
2007: Claudine Graf; Florian Heidel; Stefan Tenzer; Markus P Radsak; Fian K Solem; Cedrik Michael Britten; Christoph Huber; Thomas Fischer; Thomas Wölfel
A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.
Blood 2007;109(7):2985-8.
2007: Florian Heidel; Jorge Cortes; Frank G Rücker; Walter Aulitzky; Laurie Letvak; Thomas Kindler; Christoph Huber; Hartmut Döhner; Andrew Lamb; Thomas Fischer
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Cancer 2007;109(5):907-14.
2006: Marcus Schuchmann; Henning Schulze-Bergkamen; Binje Fleischer; Jörn M Schattenberg; Juergen Siebler; Arndt Weinmann; Andreas Teufel; Marcus A Wörns; Thomas Fischer; Susanne Strand; Ansgar W Lohse; Peter R Galle
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Oncology reports 2006;15(1):227-30.
2006: Florian Heidel; Fian K Solem; Frank Breitenbuecher; Daniel B Lipka; Stefan Kasper; M H Thiede; Christian Brandts; Hubert Serve; Johannes Roesel; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary J Schiller; Stephen D Nimer; Richard M Stone; Yanfeng Wang; Thomas Kindler; Pamela S Cohen; Christoph Huber; Thomas Fischer
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Blood 2006;107(1):293-300.
2005: Georg Hess; Donald Bunjes; Wolfgang Siegert; Rainer Schwerdtfeger; Georg Ledderose; Barbara Wassmann; Guido Kobbe; Martin Bornhäuser; Andreas Hochhaus; Andrew J Ullmann; Thomas Kindler; Ulrike Haus; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7583-93.
2005: Chunaram Choudhary; Joachim Schwäble; Christian Brandts; Lara Tickenbrock; Bülent Sargin; Thomas Kindler; Thomas Fischer; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Blood 2005;106(1):265-73.
2005: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; Elihu Estey; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary Schiller; Virginia Klimek; Stephen D Nimer; Alois Gratwohl; Chunaram Choudhary; Constan Mueller-Tidow; Hubert Serve; Harald Gschaidmeier; Pamela S Cohen; Christoph Huber; Thomas Fischer
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Andreas Kreft; Jürgen Burg; Thomas Fischer; Charles James Kirkpatrick
Essential thrombocythemia terminating in pure erythroleukemia.
American journal of hematology 2004;77(2):140-3.
2004: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Joachim Beck; Georg Hess; Birgit Weinkauf; Justus Duyster; Christian Peschel; Charles James Kirkpatrick; Matthias Theobald; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Blood 2004;103(10):3644-54.
2003: Andrew J Ullmann; Georg Hess; Karin Kolbe; A Friedrich-Freksa; Ralf G Meyer; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
The Keio journal of medicine 2003;52(3):182-8.
2003: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; T Stevens; B Carius; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Leukemia 2003;17(6):999-1009.
2003: Georg Hess; Thomas Flohr; Christoph Huber; Karin Kolbe; Hans Günter Derigs; Thomas Fischer
Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Bone marrow transplantation 2003;31(9):775-82.
2003: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Georg Hess; Harald Gschaidmeier; Heinold Gamm; Charles James Kirkpatrick; Christoph Huber; Thomas Fischer
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Blood 2003;101(8):2960-2.
2002: Thomas Fischer; C Reifenrath; G R Hess; Maria T Corsetti; Sebastian Kreil; J Beck; P Meinhardt; Germana Beltrami; B Schuch; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus; A Carella; Christoph Huber
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Leukemia 2002;16(7):1220-8.
2002: Thomas Kindler; Ralf G Meyer; Thomas Fischer
BCR-ABL as a target for novel therapeutic interventions.
Expert opinion on therapeutic targets 2002;6(1):85-101.
2002: Thomas Fischer
[Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():22-7.
2001: Sebastian Kreiter; N Winkelmann; Peter M Schneider; Martin Schuler; Thomas Fischer; Andrew J Ullmann; Christoph Huber; Hans Günter Derigs; Karin Kolbe
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Bone marrow transplantation 2001;28(2):157-61.
2001: M Lindauer; Thomas Fischer
Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.
Leukemia & lymphoma 2001;41(5-6):523-33.
2001: Thomas Kindler; Christine Schindel; U Brass; Thomas Fischer
Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.
Bone marrow transplantation 2001;27(2):217-8.
2000: Christine Schindel; U Siepmann; S Han; A J Ullmann; E Mayer; Thomas Fischer; Markus J Maeurer
Persistent Legionella infection in a patient after bone marrow transplantation.
Journal of clinical microbiology 2000;38(11):4294-5.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; T Westermeier; Thomas Flohr; D Desprès; Heinold Gamm; J Decker; G Derigs; Walter Aulitzky; Christoph Huber
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied.
Annals of hematology 1998;77(1-2):21-6.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; Sebastian Kreiter; Walter Aulitzky; Rüdiger Hehlmann; Christoph Huber
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
Bone marrow transplantation 1998;21(10):1029-36.
1996: S Jaharul Haque; H van der Kuip; A Kumar; Walter Aulitzky; M N Rutherford; Christoph Huber; Thomas Fischer; Bryan R G Williams
Overexpression of mouse p140 subunit of replication factor C accelerates cellular proliferation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(3):319-26.
1996: Thomas Fischer; J Aman; H van der Kuip; G Rudolf; Christian Peschel; Walter Aulitzky; Christoph Huber
Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.
British journal of haematology 1996;92(3):595-603.
1996: T Albrecht; R Schwab; Christian Peschel; H J Engels; Thomas Fischer; Christoph Huber; Walter Aulitzky
Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.
Annals of hematology 1996;72(2):73-9.
1995: R Schwab; Christian Peschel; D Desprès; G Derigs; Thomas Fischer; Christoph Huber; Walter Aulitzky
Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia.
Cytokines and molecular therapy 1995;1(4):281-8.